Why Shares of Bluebird Bio, CRISPR Therapeutics, and Editas Medicine Soared This WeekThe Motley Fool • 07/08/22
Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of CancerGlobeNewsWire • 06/07/22
Editas (EDIT) Down 20.7% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/03/22
Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual MeetingGlobeNewsWire • 05/18/22
Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta ThalassemiaZacks Investment Research • 05/13/22
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta ThalassemiaGlobeNewsWire • 05/12/22
Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the Association for Research in Vison and Ophthalmology ConferenceGlobeNewsWire • 05/04/22
Editas Medicine, Inc. (EDIT) CEO Jim Mullen on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/04/22
Editas Medicine to Present Pipeline and Platform Data Demonstrating Progress Towards Developing Transformative Gene Editing Medicines at the American Society of Gene and Cell Therapy Annual MeetingGlobeNewsWire • 05/02/22
Editas Medicine (EDIT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 04/27/22
Editas Medicine to Host Conference Call Discussing First Quarter 2022 Results and Corporate UpdateGlobeNewsWire • 04/27/22
Editas Medicine Receives FDA Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Beta ThalassemiaGlobeNewsWire • 04/26/22
Editas (EDIT) Begins Dosing Pediatric Patients in Gene Drug StudyZacks Investment Research • 04/12/22
Editas Medicine Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10GlobeNewsWire • 04/11/22
Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual MeetingGlobeNewsWire • 04/08/22